Adaptive Bio (ADPT) Stock Forecast, Price Target & Predictions
ADPT Stock Forecast
Adaptive Bio stock forecast is as follows: an average price target of $12.33 (represents a 166.31% upside from ADPT’s last price of $4.63) and a rating consensus of 'Hold', based on 12 wall street analysts offering a 1-year stock forecast.
ADPT Price Target
The average price target for Adaptive Bio (ADPT) is $12.33 based on 1-year price targets from 12 Wall Street analysts in the past 3 months, with a price target range of $18.00 to $5.00. This represents a potential 166.31% upside from ADPT's last price of $4.63.
ADPT Analyst Ratings
According to 12 Wall Street analysts, Adaptive Bio's rating consensus is 'Hold'. The analyst rating breakdown for ADPT stock is 0 'Strong Buy' (0.00%), 4 'Buy' (33.33%), 7 'Hold' (58.33%), 1 'Sell' (8.33%), and 0 'Strong Sell' (0.00%).
Adaptive Bio Price Target by Analyst
| Date | Analyst | Company | Price Target | Price when Published | Price Target/Price when Published | Price Target/Last Closing Price |
|---|---|---|---|---|---|---|
| Apr 04, 2024 | Mark Massaro | BTIG | $5.00 | $2.68 | 86.57% | 7.99% |
| Dec 21, 2022 | David Westenberg | Piper Sandler | $14.00 | $7.09 | 97.46% | 202.38% |
| Aug 17, 2022 | David Westenberg | Piper Sandler | $12.00 | $11.55 | 3.90% | 159.18% |
| Jun 13, 2022 | David Westenberg | Piper Sandler | $7.50 | $6.97 | 7.60% | 61.99% |
| May 06, 2022 | - | Morgan Stanley | $18.00 | $8.15 | 120.86% | 288.77% |
The latest Adaptive Bio stock forecast, released on Apr 04, 2024 by Mark Massaro from BTIG, set a price target of $5.00, which represents a 86.57% increase from the stock price at the time of the forecast ($2.68), and a 7.99% increase from ADPT last price ($4.63).
Adaptive Bio Price Target by Period
| 1M | 3M | 12M | |
|---|---|---|---|
| # Anlaysts | - | - | 1 |
| Avg Price Target | - | - | $5.00 |
| Last Closing Price | $4.63 | $4.63 | $4.63 |
| Upside/Downside | -100.00% | -100.00% | 7.99% |
In the current month, the average price target of Adaptive Bio stock is -, according to 0 Wall Street analyst offering twelve months forecast. The average price target represents a -100.00% decrease as opposed to Adaptive Bio's last price of $4.63. This month's average price target is down NaN% compared to last quarter, and down -100.00% compared to last year.
Analyst Ratings Upgrades/Downgrades
| Date | Company | Previous Rating | New Rating | Rating Change |
|---|---|---|---|---|
| Apr 04, 2024 | BTIG | Buy | Buy | Hold |
| Jan 05, 2023 | Scotiabank | - | Sector Outperform | Initialise |
| Dec 21, 2022 | Piper Sandler | Neutral | Overweight | Upgrade |
| Dec 21, 2022 | Morgan Stanley | - | Equal-Weight | Downgrade |
| Dec 21, 2022 | BMO Capital | - | Market Perform | Downgrade |
| Dec 21, 2022 | Citigroup | - | Neutral | Initialise |
| Dec 21, 2022 | Barclays | - | Equal-Weight | Initialise |
| Dec 21, 2022 | Roth Capital | - | Buy | Initialise |
| Dec 21, 2022 | Jefferies | - | Buy | Initialise |
| Dec 21, 2022 | SMBC Nikko | - | Neutral | Initialise |
Adaptive Bio's last stock rating was published by BTIG on Apr 04, 2024. The company gave ADPT a "Buy" rating, the same as its previous rate.
Adaptive Bio Financial Forecast
Adaptive Bio Revenue Forecast
| Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jul 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | - | - | - | - | - | - | $45.78M | $37.92M | $48.93M | $37.65M | $55.20M | $47.83M | - | $38.62M | $37.93M | $39.47M | $38.51M | $38.44M | $30.18M | $26.30M | $20.99M | $20.91M | $24.21M | $26.06M |
| Avg Forecast | $69.11M | $59.30M | $62.03M | $56.72M | $57.87M | $51.09M | $51.10M | $46.41M | $47.07M | $40.32M | $38.63M | $38.78M | $48.45M | $42.96M | $44.87M | $36.81M | $54.72M | $47.81M | $41.81M | $37.77M | $36.37M | $36.63M | $31.27M | $27.72M | $26.89M | $23.59M | $18.80M | $22.34M | $21.71M | $22.10M |
| High Forecast | $71.50M | $61.35M | $64.17M | $58.68M | $59.87M | $52.85M | $52.86M | $48.01M | $48.69M | $40.84M | $39.97M | $40.11M | $58.93M | $47.00M | $46.42M | $38.08M | $56.61M | $49.46M | $41.81M | $39.63M | $38.15M | $38.43M | $32.80M | $29.08M | $28.21M | $24.75M | $19.72M | $23.44M | $22.78M | $23.18M |
| Low Forecast | $64.81M | $55.61M | $58.17M | $53.19M | $54.27M | $47.91M | $47.91M | $43.52M | $44.14M | $39.95M | $36.23M | $36.36M | $44.15M | $40.90M | $42.08M | $34.52M | $51.32M | $44.83M | $41.81M | $35.97M | $34.63M | $34.88M | $29.77M | $26.39M | $25.60M | $22.46M | $17.90M | $21.27M | $20.67M | $21.04M |
| # Analysts | 3 | 3 | 3 | 3 | 4 | 4 | 4 | 4 | 3 | 6 | 3 | 4 | 5 | 8 | 5 | 4 | 4 | 3 | 5 | 2 | 3 | 3 | 3 | 3 | 4 | 4 | 4 | 4 | 2 | 2 |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | 0.94% | 0.88% | 1.09% | 1.02% | 1.01% | 1.00% | - | 1.02% | 1.04% | 1.08% | 1.23% | 1.39% | 1.12% | 1.11% | 1.12% | 0.94% | 1.11% | 1.18% |
Adaptive Bio's average Quarter revenue forecast for Mar 24 based on 4 analysts is $38.78M, with a low forecast of $36.36M, and a high forecast of $40.11M. ADPT's average Quarter revenue forecast represents a -15.31% decrease compared to the company's last Quarter revenue of $45.78M (Dec 23).
Adaptive Bio EBITDA Forecast
| Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jul 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 3 | 3 | 3 | 3 | 4 | 4 | 4 | 4 | 3 | 6 | 3 | 4 | 5 | 8 | 5 | 4 | 4 | 3 | 5 | 2 | 3 | 3 | 3 | 3 | 4 | 4 | 4 | 4 | 2 | 2 |
| EBITDA | - | - | - | - | - | - | - | - | - | - | - | - | $-40.25M | $-50.96M | $-47.82M | $-48.75M | $-36.16M | $-39.28M | - | $-58.01M | $-56.49M | $-52.47M | $-46.40M | $-37.97M | $-41.10M | $-33.89M | $-33.02M | $-29.75M | $-18.54M | $-11.89M |
| Avg Forecast | $-67.75M | $-58.14M | $-60.81M | $-55.60M | $-56.73M | $-50.09M | $-50.09M | $-45.49M | $-46.14M | $-39.52M | $-37.87M | $-72.56M | $-47.50M | $-42.11M | $-43.99M | $-65.96M | $-53.64M | $-61.74M | $-40.99M | $-59.97M | $-56.49M | $-56.13M | $-55.03M | $-49.08M | $-35.43M | $-35.10M | $-35.38M | $-22.31M | $-21.32M | $-16.49M |
| High Forecast | $-63.53M | $-54.52M | $-57.03M | $-52.14M | $-53.20M | $-46.97M | $-46.97M | $-42.66M | $-43.27M | $-39.17M | $-35.51M | $-58.05M | $-43.28M | $-40.10M | $-41.25M | $-52.77M | $-50.30M | $-49.40M | $-40.99M | $-47.97M | $-45.19M | $-44.90M | $-44.02M | $-39.27M | $-28.35M | $-28.08M | $-28.30M | $-17.85M | $-17.05M | $-13.19M |
| Low Forecast | $-70.09M | $-60.14M | $-62.91M | $-57.52M | $-58.69M | $-51.81M | $-51.82M | $-47.06M | $-47.73M | $-40.04M | $-39.18M | $-87.07M | $-57.77M | $-46.08M | $-45.51M | $-79.16M | $-55.49M | $-74.09M | $-40.99M | $-71.96M | $-67.79M | $-67.36M | $-66.03M | $-58.90M | $-42.52M | $-42.12M | $-42.45M | $-26.77M | $-25.58M | $-19.79M |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | 0.85% | 1.21% | 1.09% | 0.74% | 0.67% | 0.64% | - | 0.97% | 1.00% | 0.93% | 0.84% | 0.77% | 1.16% | 0.97% | 0.93% | 1.33% | 0.87% | 0.72% |
undefined analysts predict ADPT's average Quarter EBITDA for undefined to be $NaN, with a high of $NaN and a low of $NaN. This is NaN% lower than Adaptive Bio's previous annual EBITDA (undefined) of $NaN.
Adaptive Bio Net Income Forecast
| Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jul 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 3 | 3 | 3 | 3 | 4 | 4 | 4 | 4 | 3 | 6 | 3 | 4 | 5 | 8 | 5 | 4 | 4 | 3 | 5 | 2 | 3 | 3 | 3 | 3 | 4 | 4 | 4 | 4 | 2 | 2 |
| Net Income | - | - | - | - | - | - | - | - | - | - | - | - | $-69.44M | $-50.30M | $-47.81M | $-61.74M | $-24.52M | $-45.17M | - | $-62.52M | $-61.34M | $-56.00M | $-49.30M | $-40.64M | $-44.57M | $-36.72M | $-33.53M | $-31.40M | $-20.61M | $-13.95M |
| Avg Forecast | $-28.01M | $-31.69M | $-29.48M | $-36.12M | $-35.63M | $-38.23M | $-37.98M | $-42.91M | $-42.79M | $-42.20M | $-49.25M | $-79.29M | $-48.84M | $-49.92M | $-51.13M | $-72.08M | $-51.12M | $-65.90M | $-62.44M | $-65.53M | $-61.34M | $-59.90M | $-58.47M | $-52.54M | $-38.42M | $-38.03M | $-35.93M | $-23.55M | $-23.70M | $-19.36M |
| High Forecast | $-25.74M | $-29.13M | $-27.10M | $-33.19M | $-32.74M | $-35.13M | $-34.91M | $-39.44M | $-39.33M | $-37.98M | $-45.26M | $-63.43M | $-45.79M | $-33.77M | $-46.99M | $-57.66M | $-46.98M | $-52.72M | $-62.44M | $-52.42M | $-49.07M | $-47.92M | $-46.78M | $-42.03M | $-30.74M | $-30.42M | $-28.74M | $-18.84M | $-18.96M | $-15.48M |
| Low Forecast | $-29.26M | $-33.12M | $-30.81M | $-37.74M | $-37.22M | $-39.94M | $-39.68M | $-44.84M | $-44.71M | $-49.24M | $-51.46M | $-95.14M | $-53.42M | $-54.33M | $-53.42M | $-86.49M | $-53.41M | $-79.07M | $-62.44M | $-78.63M | $-73.61M | $-71.89M | $-70.17M | $-63.04M | $-46.11M | $-45.64M | $-43.12M | $-28.26M | $-28.44M | $-23.23M |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | 1.42% | 1.01% | 0.94% | 0.86% | 0.48% | 0.69% | - | 0.95% | 1.00% | 0.93% | 0.84% | 0.77% | 1.16% | 0.97% | 0.93% | 1.33% | 0.87% | 0.72% |
Adaptive Bio's average Quarter net income forecast for undefined is $NaN, with a range of $NaN to $NaN. ADPT's average Quarter net income forecast represents a NaN% decrease compared to the company's last Quarter net income of $NaN (undefined).
Adaptive Bio SG&A Forecast
| Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jul 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 3 | 3 | 3 | 3 | 4 | 4 | 4 | 4 | 3 | 6 | 3 | 4 | 5 | 8 | 5 | 4 | 4 | 3 | 5 | 2 | 3 | 3 | 3 | 3 | 4 | 4 | 4 | 4 | 2 | 2 |
| SG&A | - | - | - | - | - | - | - | - | - | - | - | - | $42.63M | $40.57M | $46.17M | $43.14M | $46.14M | $42.27M | - | $50.24M | $50.04M | $45.10M | $39.28M | $35.54M | $31.94M | $26.55M | $26.57M | $25.83M | $20.83M | $17.58M |
| Avg Forecast | $69.72M | $59.82M | $62.58M | $57.22M | $58.38M | $51.54M | $51.54M | $46.81M | $47.48M | $40.67M | $38.97M | $39.12M | $48.88M | $43.34M | $45.27M | $37.13M | $55.20M | $48.23M | $42.17M | $38.10M | $36.69M | $36.95M | $31.54M | $27.96M | $27.12M | $23.80M | $18.96M | $19.37M | $21.90M | $22.29M |
| High Forecast | $72.12M | $61.89M | $64.74M | $59.19M | $60.39M | $53.32M | $53.32M | $48.43M | $49.12M | $41.20M | $40.31M | $40.46M | $59.45M | $47.41M | $46.83M | $38.41M | $57.11M | $49.89M | $42.17M | $39.98M | $38.49M | $38.77M | $33.09M | $29.33M | $28.45M | $24.97M | $19.90M | $23.25M | $22.98M | $23.38M |
| Low Forecast | $65.38M | $56.10M | $58.68M | $53.65M | $54.74M | $48.33M | $48.33M | $43.90M | $44.52M | $40.30M | $36.54M | $36.68M | $44.54M | $41.26M | $42.45M | $34.82M | $51.76M | $45.23M | $42.17M | $36.28M | $34.93M | $35.18M | $30.03M | $26.62M | $25.82M | $22.66M | $18.06M | $15.50M | $20.85M | $21.22M |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | 0.87% | 0.94% | 1.02% | 1.16% | 0.84% | 0.88% | - | 1.32% | 1.36% | 1.22% | 1.25% | 1.27% | 1.18% | 1.12% | 1.40% | 1.33% | 0.95% | 0.79% |
Adaptive Bio's average Quarter SG&A projection for Mar 24 is $39.12M, based on 4 Wall Street analysts, with a range of $36.68M to $40.46M. The forecast indicates a -8.25% fall compared to ADPT last annual SG&A of $42.63M (Dec 23).
Adaptive Bio EPS Forecast
| Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jul 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 3 | 3 | 3 | 3 | 4 | 4 | 4 | 4 | 3 | 6 | 3 | 4 | 5 | 8 | 5 | 4 | 4 | 3 | 5 | 2 | 3 | 3 | 3 | 3 | 4 | 4 | 4 | 4 | 2 | 2 |
| EPS | - | - | - | - | - | - | - | - | - | - | - | - | $-0.48 | $-0.35 | $-0.33 | $-0.43 | $-0.17 | $-0.32 | - | $-0.44 | $-0.43 | $-0.40 | $-0.35 | $-0.29 | $-0.33 | $-0.27 | $-0.26 | $-0.25 | $-0.17 | $-0.11 |
| Avg Forecast | $-0.19 | $-0.21 | $-0.20 | $-0.24 | $-0.24 | $-0.26 | $-0.26 | $-0.29 | $-0.29 | $-0.29 | $-0.33 | $-0.35 | $-0.33 | $-0.34 | $-0.35 | $-0.38 | $-0.35 | $-0.36 | $-0.43 | $-0.45 | $-0.45 | $-0.42 | $-0.42 | $-0.40 | $-0.29 | $-0.28 | $-0.28 | $-0.21 | $-0.20 | $-0.25 |
| High Forecast | $-0.17 | $-0.20 | $-0.18 | $-0.23 | $-0.22 | $-0.24 | $-0.24 | $-0.27 | $-0.27 | $-0.26 | $-0.31 | $-0.32 | $-0.31 | $-0.23 | $-0.32 | $-0.35 | $-0.32 | $-0.33 | $-0.43 | $-0.42 | $-0.42 | $-0.40 | $-0.39 | $-0.38 | $-0.28 | $-0.26 | $-0.26 | $-0.20 | $-0.19 | $-0.23 |
| Low Forecast | $-0.20 | $-0.22 | $-0.21 | $-0.26 | $-0.25 | $-0.27 | $-0.27 | $-0.30 | $-0.30 | $-0.33 | $-0.35 | $-0.36 | $-0.36 | $-0.37 | $-0.36 | $-0.39 | $-0.36 | $-0.38 | $-0.43 | $-0.48 | $-0.48 | $-0.45 | $-0.44 | $-0.43 | $-0.31 | $-0.30 | $-0.30 | $-0.22 | $-0.21 | $-0.26 |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | 1.45% | 1.03% | 0.95% | 1.14% | 0.49% | 0.88% | - | 0.97% | 0.95% | 0.95% | 0.84% | 0.72% | 1.12% | 0.96% | 0.92% | 1.20% | 0.86% | 0.44% |
According to undefined Wall Street analysts, Adaptive Bio's projected average Quarter EPS for undefined is $NaN, with a low estimate of $NaN and a high estimate of $NaN. This represents a NaN% decrease compared to ADPT previous annual EPS of $NaN (undefined).
Adaptive Bio Peer Comparison by Price Target
| Ticker | Company | Last Closing Price | Avg Price Target | Upside/Downside | Avg Rating |
|---|---|---|---|---|---|
| HEPA | Hepion Pharmaceuticals | $0.70 | $70.00 | 9900.00% | Buy |
| ELEV | Elevation Oncology | $0.60 | $9.00 | 1400.00% | Buy |
| RPHM | Reneo Pharmaceuticals | $1.39 | $18.00 | 1194.96% | Buy |
| KNTE | Kinnate Biopharma | $2.65 | $30.00 | 1032.08% | Hold |
| VERV | Verve Therapeutics | $5.39 | $21.50 | 298.89% | Buy |
| VIR | Vir Bio | $7.93 | $26.60 | 235.44% | Buy |
| SANA | Sana Bio | $4.30 | $12.00 | 179.07% | Buy |
| ADPT | Adaptive Bio | $4.63 | $12.33 | 166.31% | Hold |
| BEAM | Beam Therapeutics | $25.58 | $64.20 | 150.98% | Buy |
| APLS | Apellis Pharmaceuticals | $35.53 | $75.38 | 112.16% | Buy |
| LEGN | Legend Biotech | $51.17 | $78.78 | 53.96% | Buy |
| RPRX | Royalty Pharma | $28.24 | $43.33 | 53.43% | Buy |
| CRBU | Caribou Biosciences | $2.10 | $3.00 | 42.86% | Buy |
| ZURA | Zura Bio | $3.88 | $5.00 | 28.87% | Buy |
| VECT | VectivBio | $16.87 | $18.00 | 6.70% | Buy |
| KRYS | Krystal Biotech | $189.26 | $191.00 | 0.92% | Buy |
| IKNA | Ikena Oncology | $1.67 | $1.33 | -20.36% | Buy |
ADPT Forecast FAQ
Is Adaptive Bio a good buy?
No, according to 12 Wall Street analysts, Adaptive Bio (ADPT) is considered a 'Hold'. The rating consensus is based on 0 'Strong Buy' and 4 'Buy' recommendations, accounting for 33.33% of ADPT's total ratings.
What is ADPT's price target?
Adaptive Bio (ADPT) average price target is $12.33 with a range of $5 to $18, implying a 166.31% from its last price of $4.63. The data is based on 12 Wall Street analysts who provided a twelve-month price target estimate in the last three months.
Will Adaptive Bio stock go up soon?
According to Wall Street analysts' prediction for ADPT stock, the company can go up by 166.31% (from the last price of $4.63 to the average price target of $12.33), up by 288.77% based on the highest stock price target, and up by 7.99% based on the lowest stock price target.
Can Adaptive Bio stock reach $7?
ADPT's average twelve months analyst stock price target of $12.33 supports the claim that Adaptive Bio can reach $7 in the near future.
What are Adaptive Bio's analysts' financial forecasts?
Adaptive Bio's analysts financial forecasts for the fiscal year (Dec 2025) are as follows: average revenue is $206.47M (high $213.59M, low $193.61M), average EBITDA is $-202M (high $-190M, low $-209M), average net income is $-155M (high $-142M, low $-162M), average SG&A $208.27M (high $215.45M, low $195.3M), and average EPS is $-1.05 (high $-0.965, low $-1.097). ADPT's analysts financial forecasts for the fiscal year (Dec 2026) are as follows: average revenue is $247.18M (high $255.7M, low $231.78M), average EBITDA is $-242M (high $-227M, low $-251M), average net income is $-125M (high $-115M, low $-131M), average SG&A $249.34M (high $257.94M, low $233.81M), and average EPS is $-0.85 (high $-0.781, low $-0.888).
Did the ADPT's actual financial results beat the analysts' financial forecasts?
Based on Adaptive Bio's last annual report (Dec 2023), the company's revenue was $170.28M, which missed the average analysts forecast of $173.1M by -1.63%. Apple's EBITDA was $-179M, missing the average prediction of $-200M by -10.12%. The company's net income was $-225M, beating the average estimation of $-222M by 1.48%. Apple's SG&A was $172.51M, missing the average forecast of $174.61M by -1.20%. Lastly, the company's EPS was $-1.56, beating the average prediction of $-1.394 by 11.92%. In terms of the last quarterly report (Dec 2023), Adaptive Bio's revenue was $45.78M, missing the average analysts' forecast of $48.45M by -5.51%. The company's EBITDA was $-40.247M, missing the average prediction of $-47.498M by -15.27%. Adaptive Bio's net income was $-69.441M, beating the average estimation of $-48.84M by 42.18%. The company's SG&A was $42.63M, missing the average forecast of $48.88M by -12.77%. Lastly, the company's EPS was $-0.48, beating the average prediction of $-0.331 by 44.88%